.jpg)
This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.
Human medicines European public assessment report (EPAR): RoActemra, tocilizumab...
The Fierce Biotech Fundraising Tracker records venture capital rounds of $50 mil...
Human medicines European public assessment report (EPAR): Jinarc, tolvaptan, Dat...
Human medicines European public assessment report (EPAR): MabThera, rituximab, D...
The delayed decision comes amid a major organizational shakeup that included the...
Human medicines European public assessment report (EPAR): Seffalair Spiromax, sa...
A report by a New York congressman details consumer and employee grievances with...
Human medicines European public assessment report (EPAR): ellaOne, ulipristal ac...
While the FDA’s inspection figures for drug manufacturing facilities have yet to...
Human medicines European public assessment report (EPAR): Camcevi, leuprorelin, ...
And more crucial biotech news stories, brought to you by The Readout.
The Trump administration carved out an exception for pharmaceuticals from the pr...
Roche has reported preliminary results on its Alzheimer’s disease prospect tront...
The FDA has set back Aldeyra Therapeutics’ ambitions to win approval for its dry...
Health news stories you need to read this morning.
Agencies made moves on both sides of the Atlantic Wednesday, with Havas Health s...
Human medicines European public assessment report (EPAR): Tukysa, tucatinib, Dat...
A paper proposing NIH reforms is circulating in academic circles and within the ...
Reflection paper on use of real-world data in non-interventional studies to gene...
Journey towards a roadmap for regulatory guidance on real-world evidence
BeiGene is scrapping ociperlimab over a disappointing phase 3 outlook two years ...
Human medicines European public assessment report (EPAR): Litak, cladribine, Dat...
Human medicines European public assessment report (EPAR): Yondelis, trabectedin,...